GlassScriptPhysician profile
James V Agresti
NPI 1578511135
$7,299.65
in general payments reported to CMS, 2019-2025
61 companies · $826 in 2025
The $826 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,012 · 2020: $1,081 · 2021: $1,004 · 2022: $1,048 · 2023: $1,250 · 2024: $1,078 · 2025: $826.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,153.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $722.16 | 2019-2025 | Breztri, Farxiga, Lokelma |
| Lilly USA, LLC | $608.36 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Novo Nordisk INC | $586.54 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $477.18 | 2020-2025 | Jardiance, Spiriva Respimat |
| Amgen INC. | $401.16 | 2019-2025 | Otezla, Repatha, Repatha |
| Sanofi-Aventis U.S. LLC | $333.12 | 2019-2023 | |
| Pfizer INC. | $324.20 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $214.22 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $204.78 | 2020-2025 | Zoryve, Livalo, Seglentis |
| Sunovion Pharmaceuticals INC. | $198.94 | 2019-2022 | |
| Exact Sciences Corporation | $194.55 | 2023-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $183.61 | 2021-2025 | Rexulti, Nuedexta |
| Glaxosmithkline, LLC. | $181.04 | 2020-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Amarin Pharma, INC. | $176.92 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $167.54 | 2019-2022 |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Agresti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.